MBX Biosciences Statistics
Total Valuation
MBX Biosciences has a market cap or net worth of $372.35 million. The enterprise value is $110.37 million.
| Market Cap | 372.35M |
| Enterprise Value | 110.37M |
Important Dates
The last earnings date was Monday, May 12, 2025, before market open.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MBX Biosciences has 33.42 million shares outstanding. The number of shares has increased by 1,591.63% in one year.
| Current Share Class | 33.42M |
| Shares Outstanding | 33.42M |
| Shares Change (YoY) | +1,591.63% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 3.16% |
| Owned by Institutions (%) | 43.69% |
| Float | 13.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -31.10% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.71M |
| Employee Count | 43 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 8.75 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 62.73 |
| Average Volume (20 Days) | 289,128 |
Short Selling Information
The latest short interest is 5.38 million, so 16.10% of the outstanding shares have been sold short.
| Short Interest | 5.38M |
| Short Previous Month | 5.36M |
| Short % of Shares Out | 16.10% |
| Short % of Float | 39.55% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -81.41M |
| Pretax Income | -47.20M |
| Net Income | -73.47M |
| EBITDA | -81.15M |
| EBIT | -81.41M |
| Earnings Per Share (EPS) | -$3.93 |
Balance Sheet
The company has $262.15 million in cash and $171,000 in debt, giving a net cash position of $261.98 million or $7.84 per share.
| Cash & Cash Equivalents | 262.15M |
| Total Debt | 171,000 |
| Net Cash | 261.98M |
| Net Cash Per Share | $7.84 |
| Equity (Book Value) | 257.44M |
| Book Value Per Share | 7.70 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MBX Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,591.63% |
| Shareholder Yield | -1,591.63% |
| Earnings Yield | -19.73% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MBX Biosciences is $37.40, which is 235.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $37.40 |
| Price Target Difference | 235.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |